Product labeling for PO topotecan endorses avoiding concomitant usage of P-gp inhibitors; the interaction with IV topotecan could possibly be significantly less critical but remains likely of clinical significanceaspirin, cilostazol. Either increases toxicity of the other by pharmacodynamic synergism. Use Caution/Keep track of. The need for simulta